Navigation Links
Eczema Non-Profit Seeks To Shine New Light On Overlooked Condition
Date:7/1/2012

Indian Harbour Beach, Florida (PRWEB) July 01, 2012

ITSAN, a non-profit charity, is on a mission to combat the global health crisis that is Topical Steroid Addiction. The organization’s main effort is to reach Eczema patients with information about the correlation between Topical Steroids and worsening Eczema. Topical Steroids are the main medication used to treat Eczema.

“In 30 years of practice I have seen over 2,000 patients who initially had Eczema, either in youth, teen years or early adulthood. Each patient started off using Cortisone Creams. When the initial dose and potency no longer worked they were prescribed a higher potency with more frequent usage. In addition often pills and injections of cortisone were given,” recounts Dr. Rapaport.

“In all cases we decided to stop steroids and lo and behold, in one to three years, they were all cured. However, in each case the patient experienced a painful and debilitating withdrawal. They would swell, ooze, have difficulty functioning in school or work, scratch continually, and couldn’t sleep; we had to support them with other medication and keep them off steroids,” stated Dr. Rapaport.

Kelly Palace, president and Co-Founder of ITSAN, was diagnosed in 2009 with Steroid Induced Eczema caused by her Topical Steroid Addiction. Kelly decided to start a website to chronicle her recovery and alert people of the dangers associated with Topical Steroids. Since starting the site she has had over 100,000 web visits.

“I was critically covered in full body Eczema with no recourse. I was given Corticosteroid after Corticosteroid and told there was nothing else I could do. I was getting worse and worse until I found Dr. Rapaport’s articles; he saved my life,” said ITSAN President Kelly Palace.

Kelly discovered thousands of people like her, over the Internet, suffering the same Eczema like “incurable” symptoms. Whenever they stopped applying Topical Steroids their skin would flare, burn, and turn red. “Once we each discovered the research, which depicted these exact withdrawal symptoms, we knew our cure was in sight,” said Kelly Palace.

ITSAN’s goals include educating Eczema patients about this medical issue. Gaining more recognition amongst the broader medical community about Topical Steroid Addiction. Labeling changes to Topical Steroids to better warn patients, and patient treatment options for a monitored and less painful withdrawal process.

Kelly Palace has high hopes for those who are still suffering. “We hope that if you’re suffering that you get the help and support you need from the ITSAN resources and our global, community support groups.”

To learn more about Dr. Marvin Rapaport and his research on Topical Steroid Addiction, please visit http://itsan.org/research-and-resources.html#Dr._Marvin_Rapaport

About The International Topical Steroid Addiction Network

ITSAN was officially Co-Founded by Dermatologist Dr. Marvin Rapaport, full professor at UCLA Medical Center and the nations leading expert on the subject. Kelly Palace, Co-Founder and president, was one of the 2,000 patients that Dr. Rapaport treated and cured. An online community of over 100 patients with this condition also contributed ideas, money and inspiration to start ITSAN. For more information please visit http://itsan.org

Read the full story at http://www.prweb.com/releases/2012/7/prweb9659853.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. Prenatal Exposure to Common Household Chemical Linked to Eczema
2. Prenatal exposure to common household chemical increases risk for childhood eczema, study says
3. Avid Collector Seeks Jimi Hendrix 1968 Electric Factory Philadelphia Concert Poster
4. Electronic data methods research seeks to build a learning health care system
5. Trial seeks to sniff out cancer
6. FDA Seeks to Limit Antibiotics in Animal Feed
7. Lighthouse Worldwide Solutions Now Monitors Air Quality in Hospitals and Operating Rooms
8. Bees shed light on human sweet perception and metabolic disorders
9. DRE Medical Equipment Unveils FX-300+ Surgical Headlight and Light Source
10. Special Needs Spotlight: Former SFMTA Board Member Bruce Oka Receives Treatment with San Francisco Sedation Dentist Dr. David Blende
11. Could Sunlight Lower Your Odds for Pancreatic Cancer?
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2017)... ... July 28, 2017 , ... Lundquist Insurance Services, a family ... and families across east Texas, is embarking on a charity event in conjunction ... area. , America’s Mighty Warriors offers a series of programs for veterans that ...
(Date:7/28/2017)... ... 2017 , ... Leyden Insurance Agency, a Chicago based firm that offers asset ... County, is working in conjunction with the Conner T. Lowry Memorial Fund in a ... of a brave soldier who is still dearly missed by his community, the Connor ...
(Date:7/27/2017)... ... 2017 , ... Conventus, New Jersey’s premier professional liability insurer ... new educational series of webinars and podcasts to guide medical practices on understanding ... The first two episodes of the series, entitled “Pain Management and Opioids: New ...
(Date:7/27/2017)... (PRWEB) , ... July 27, 2017 , ... ... Diplomate of the American Board of Oral Implantology/Implant Dentistry (ABOI/ID). After successfully completing ... the nation’s leading providers of dental implants . Dr. Kimowitz and his ...
(Date:7/27/2017)... ... ... Standard Process is ushering in a new era of innovation with the ... (NCRC) in Kannapolis, North Carolina and by announcing a new leadership team, board and ... occupying over 10,000 square feet on the first floor of the David H. Murdock ...
Breaking Medicine News(10 mins):
(Date:7/27/2017)... 27, 2017  West Pharmaceutical Services, Inc. (NYSE: ... the second-quarter 2017 and updated financial guidance for the ... 2017 Highlights Reported net sales of ... prior-year quarter. Net sales at constant currency (organic) grew ... was $0.51, compared to $0.60 in the prior-year quarter. ...
(Date:7/25/2017)... Massachusetts , July 25, 2017 The med-tech ... rare nervous system diseases, has concluded a worldwide license agreement ... drug SOM0226 against transthyretin amyloidosis (ATTR). Before this licensing agreement ... a Phase 2 study conducted in Europe ... the United States ...
(Date:7/21/2017)... SILVER SPRING, Md. and RESEARCH ... -- United Therapeutics Corporation (NASDAQ: UTHR ) ... 2017 financial results before the market opens on Thursday, ... United Therapeutics will host a teleconference on Thursday, July ... is accessible by dialing 1-877-351-5881, with international callers dialing ...
Breaking Medicine Technology: